跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Baxalta Innovations GmbH

首页临床试验发起方与机构Baxalta Innovations GmbH

Baxalta Innovations GmbH

ACTIVE

Uferstraße 15, Orth An Der Donau, Niederösterreich, 奥地利www.baxalta.atSubsidiary

隶属于 baxalta gmbh

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

155

146 进行中

药物批准

48

批准总数

监管机构

3

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

132

85.2%

3 期

11

7.1%

4 期

2

1.3%

不适用

1

0.7%

试验状态分布

进行中（未招募）

145

93.5%

已完成

1

0.7%

尚未招募

1

0.7%

招募中

5

3.2%

撤回

3

1.9%

相关临床试验

该机构主办的试验（155）

A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the drug TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)

Jun 202475 名受试者

A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advate for children diagnosed with Severe von Willebrand Disease who experience bleeding episodes and/or will undergo major, minor or oral surgery procedures.

Apr 202427 名受试者

A study of safety, effect on the immune system and blood clotting of BAX855 (factor VIII of blood clotting) in pediatric patients who have not received treatment for their severe hemophilia A.

进行中（未招募）

A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advate for children diagnosed with Severe von Willebrand Disease who experience bleeding episodes and/or will undergo major, minor or oral surgery procedures.

进行中（未招募）

A Post Marketing Surveillance (PMS) Study of RIXUBIS in India

进行中（未招募）

A study on the long-term safety and effectiveness of rVWF in children and adults diagnosed with Severe von Willebrand Disease.

进行中（未招募）

Jun 202264 名受试者

A Study of the Safety and Tolerability of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

进行中（未招募）

May 202232 名受试者

A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the drug TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)

进行中（未招募）

Dec 202177 名受试者

第 1 页，共 20 页

药物批准

按机构分类的批准

EMA

European Medicines Agency

12

药物批准

SFDA

Saudi Food and Drug Authority

9

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

27

药物批准

近期批准

CUVITRU 200MG/ML INJECTION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

CUVITRU 200MG/ML INJECTION

CUVITRU 200MG/ML INJECTION

CUVITRU 200MG/ML INJECTION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

FEIBA 100 U/ML POLVO Y DISOLVENTE PARA SOLUCIÓN PARA PERFUSIÓN

资讯

暂无资讯文章

本页目录

概览
相关临床试验155
药物批准48
资讯

返回机构列表